Comparison of three commercially available assays for HCV RNA using the international unit standard: Implications for management of patients with chronic hepatitis C virus infection in clinical practice

Mitchell L. Shiffman, Andrea Ferreira-Gonzalez, K. Rajender Reddy, Richard K. Sterling, Velimir A. Luketic, R. Todd Stravitz, Arun J. Sanyal, Carleton T. Garrett, Maria De Medina, Eugene R Schiff

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

OBJECTIVES: The present study was performed to evaluate the impact of the international unit standard for measuring HCV RNA in the management of patients with chronic hepatitis C virus (HCV) infection. METHODS: The three assays used were Amplicor Monitor PCR, the National Genetics Institute PCR assay, and branched chain DNA. HCV RNA was measured at four time points (baseline, 3 months after the start of therapy, at the end of treatment, and 6 months after discontinuation of therapy) in 106 consecutive patients who received interferon and ribavirin for chronic HCV. RESULTS: The mean age of the patients was 44 yr. Of the patients, 62% were male, 24% were African American, 38% had bridging fibrosis or cirrhosis, and 75% were HCV genotype 1. Of the 424 samples analyzed, 82-89% of values were within 1 log unit and 85-92% were within 2 log units by the various assays. This variability was not dependent upon HCV genotype. HCV RNA was undetectable in 1.4-6.8% of samples when virus was detected by another assay. The mean HCV RNA in these discordant samples was 1.47-6.33 log IU/ml (30-2,100,000 IU/ml). CONCLUSIONS: These data demonstrate that approximately 90% of serum values for HCV RNA were within 1 log unit by the international unit standard regardless of which virological assay was used. However, false positive and false negative results as well as variations in the HCV RNA level of more than 1 to 2 log units can occur with any of the assays, and these results may have an impact upon the management of patients receiving interferon therapy. It is therefore unwise in clinical practice to base important treatment decisions upon a single HCV RNA determination.

Original languageEnglish
Pages (from-to)1159-1166
Number of pages8
JournalAmerican Journal of Gastroenterology
Volume98
Issue number5
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Virus Diseases
Hepacivirus
RNA
Interferons
Fibrosis
Branched DNA Signal Amplification Assay
Genotype
Therapeutics
Polymerase Chain Reaction
Ribavirin
African Americans
Viruses

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Comparison of three commercially available assays for HCV RNA using the international unit standard : Implications for management of patients with chronic hepatitis C virus infection in clinical practice. / Shiffman, Mitchell L.; Ferreira-Gonzalez, Andrea; Reddy, K. Rajender; Sterling, Richard K.; Luketic, Velimir A.; Stravitz, R. Todd; Sanyal, Arun J.; Garrett, Carleton T.; De Medina, Maria; Schiff, Eugene R.

In: American Journal of Gastroenterology, Vol. 98, No. 5, 01.05.2003, p. 1159-1166.

Research output: Contribution to journalArticle

Shiffman, Mitchell L. ; Ferreira-Gonzalez, Andrea ; Reddy, K. Rajender ; Sterling, Richard K. ; Luketic, Velimir A. ; Stravitz, R. Todd ; Sanyal, Arun J. ; Garrett, Carleton T. ; De Medina, Maria ; Schiff, Eugene R. / Comparison of three commercially available assays for HCV RNA using the international unit standard : Implications for management of patients with chronic hepatitis C virus infection in clinical practice. In: American Journal of Gastroenterology. 2003 ; Vol. 98, No. 5. pp. 1159-1166.
@article{c5e186630a2e49869c371dc98578fcb0,
title = "Comparison of three commercially available assays for HCV RNA using the international unit standard: Implications for management of patients with chronic hepatitis C virus infection in clinical practice",
abstract = "OBJECTIVES: The present study was performed to evaluate the impact of the international unit standard for measuring HCV RNA in the management of patients with chronic hepatitis C virus (HCV) infection. METHODS: The three assays used were Amplicor Monitor PCR, the National Genetics Institute PCR assay, and branched chain DNA. HCV RNA was measured at four time points (baseline, 3 months after the start of therapy, at the end of treatment, and 6 months after discontinuation of therapy) in 106 consecutive patients who received interferon and ribavirin for chronic HCV. RESULTS: The mean age of the patients was 44 yr. Of the patients, 62{\%} were male, 24{\%} were African American, 38{\%} had bridging fibrosis or cirrhosis, and 75{\%} were HCV genotype 1. Of the 424 samples analyzed, 82-89{\%} of values were within 1 log unit and 85-92{\%} were within 2 log units by the various assays. This variability was not dependent upon HCV genotype. HCV RNA was undetectable in 1.4-6.8{\%} of samples when virus was detected by another assay. The mean HCV RNA in these discordant samples was 1.47-6.33 log IU/ml (30-2,100,000 IU/ml). CONCLUSIONS: These data demonstrate that approximately 90{\%} of serum values for HCV RNA were within 1 log unit by the international unit standard regardless of which virological assay was used. However, false positive and false negative results as well as variations in the HCV RNA level of more than 1 to 2 log units can occur with any of the assays, and these results may have an impact upon the management of patients receiving interferon therapy. It is therefore unwise in clinical practice to base important treatment decisions upon a single HCV RNA determination.",
author = "Shiffman, {Mitchell L.} and Andrea Ferreira-Gonzalez and Reddy, {K. Rajender} and Sterling, {Richard K.} and Luketic, {Velimir A.} and Stravitz, {R. Todd} and Sanyal, {Arun J.} and Garrett, {Carleton T.} and {De Medina}, Maria and Schiff, {Eugene R}",
year = "2003",
month = "5",
day = "1",
doi = "10.1111/j.1572-0241.2003.07449.x",
language = "English",
volume = "98",
pages = "1159--1166",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Comparison of three commercially available assays for HCV RNA using the international unit standard

T2 - Implications for management of patients with chronic hepatitis C virus infection in clinical practice

AU - Shiffman, Mitchell L.

AU - Ferreira-Gonzalez, Andrea

AU - Reddy, K. Rajender

AU - Sterling, Richard K.

AU - Luketic, Velimir A.

AU - Stravitz, R. Todd

AU - Sanyal, Arun J.

AU - Garrett, Carleton T.

AU - De Medina, Maria

AU - Schiff, Eugene R

PY - 2003/5/1

Y1 - 2003/5/1

N2 - OBJECTIVES: The present study was performed to evaluate the impact of the international unit standard for measuring HCV RNA in the management of patients with chronic hepatitis C virus (HCV) infection. METHODS: The three assays used were Amplicor Monitor PCR, the National Genetics Institute PCR assay, and branched chain DNA. HCV RNA was measured at four time points (baseline, 3 months after the start of therapy, at the end of treatment, and 6 months after discontinuation of therapy) in 106 consecutive patients who received interferon and ribavirin for chronic HCV. RESULTS: The mean age of the patients was 44 yr. Of the patients, 62% were male, 24% were African American, 38% had bridging fibrosis or cirrhosis, and 75% were HCV genotype 1. Of the 424 samples analyzed, 82-89% of values were within 1 log unit and 85-92% were within 2 log units by the various assays. This variability was not dependent upon HCV genotype. HCV RNA was undetectable in 1.4-6.8% of samples when virus was detected by another assay. The mean HCV RNA in these discordant samples was 1.47-6.33 log IU/ml (30-2,100,000 IU/ml). CONCLUSIONS: These data demonstrate that approximately 90% of serum values for HCV RNA were within 1 log unit by the international unit standard regardless of which virological assay was used. However, false positive and false negative results as well as variations in the HCV RNA level of more than 1 to 2 log units can occur with any of the assays, and these results may have an impact upon the management of patients receiving interferon therapy. It is therefore unwise in clinical practice to base important treatment decisions upon a single HCV RNA determination.

AB - OBJECTIVES: The present study was performed to evaluate the impact of the international unit standard for measuring HCV RNA in the management of patients with chronic hepatitis C virus (HCV) infection. METHODS: The three assays used were Amplicor Monitor PCR, the National Genetics Institute PCR assay, and branched chain DNA. HCV RNA was measured at four time points (baseline, 3 months after the start of therapy, at the end of treatment, and 6 months after discontinuation of therapy) in 106 consecutive patients who received interferon and ribavirin for chronic HCV. RESULTS: The mean age of the patients was 44 yr. Of the patients, 62% were male, 24% were African American, 38% had bridging fibrosis or cirrhosis, and 75% were HCV genotype 1. Of the 424 samples analyzed, 82-89% of values were within 1 log unit and 85-92% were within 2 log units by the various assays. This variability was not dependent upon HCV genotype. HCV RNA was undetectable in 1.4-6.8% of samples when virus was detected by another assay. The mean HCV RNA in these discordant samples was 1.47-6.33 log IU/ml (30-2,100,000 IU/ml). CONCLUSIONS: These data demonstrate that approximately 90% of serum values for HCV RNA were within 1 log unit by the international unit standard regardless of which virological assay was used. However, false positive and false negative results as well as variations in the HCV RNA level of more than 1 to 2 log units can occur with any of the assays, and these results may have an impact upon the management of patients receiving interferon therapy. It is therefore unwise in clinical practice to base important treatment decisions upon a single HCV RNA determination.

UR - http://www.scopus.com/inward/record.url?scp=0038408809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038408809&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2003.07449.x

DO - 10.1111/j.1572-0241.2003.07449.x

M3 - Article

C2 - 12809843

AN - SCOPUS:0038408809

VL - 98

SP - 1159

EP - 1166

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 5

ER -